Nuvalent (NASDAQ:NUVL) recently publicized that the FDA gave NVL-655 their Breakthrough Therapy Designation (BTD) for locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC). The BTD press release encouraged me to do some preliminary research on Nuvalent and NVL-655. It didn't take me long to determine that NVL-655 has the potential to be a vital therapy for ALK+ NSCLC patients who often have to deal with multiple lines of therapy after their cancer develops resistance to targeted therapy aft ...

Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing ...

CAMBRIDGE, Mass., May 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to NVL-655 for the treatment of patients with locally advanced or metastatic ALK- positive non-small cell lung cancer (NSCLC) who have been previously treated with two or more AL ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-40671 NUVALENT, INC. (Exact Name of Registrant as Specified in its Charter) Delawar ...

Exhibit 99.1 Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results Updates from the ongoing Phase 1/2 ARROS-1 and ALKOVE-1 clinical trials expected at a medical meeting in the second half of 2024 Strong financial position with operating runway anticipated into 2027 Recent Pipeline Progress and Anticipated Milestones ROS1 Program ALK Program HER2 Program • Nuvalent presented new preclinical data at the American Association for Cancer Re ...

Investors are always looking for stocks that are poised to beat at earnings season and Nuvalent, Inc. (NUVL) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Nuvalent is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-K Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR Commission file number: 001-40671 NUVALENT, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) One Broadway, 14 Floor th Cambridge, MA 02142 (Address of principal executive offices) (Zip Code) (857) 357-7000 ☐ TRA ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-40671 NUVALENT, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 81-5112298 (State or other jurisdiction of incorporation or organization) One Broadway, 14 Floo ...

Financial Performance - Total current assets decreased to $436,992,000 as of June 30, 2023, down from $477,991,000 as of December 31, 2022, representing a decline of approximately 8.5%[22] - Net loss for the six months ended June 30, 2023, was $54,282,000, compared to a net loss of $36,015,000 for the same period in 2022, reflecting a 50.8% increase in losses[23] - Cash and cash equivalents decreased significantly to $70,872,000 as of June 30, 2023, from $241,806,000 as of December 31, 2022, indicating a reduction of approximately 70.7%[22] - Total stockholders' equity decreased to $421,153,000 as of June 30, 2023, down from $462,978,000 as of December 31, 2022, a decline of about 9%[22] - Comprehensive loss for Q2 2023 was $30,325,000, compared to $18,579,000 in Q2 2022, indicating a year-over-year increase of 63.5%[23] - Net cash used in operating activities for the six months ended June 30, 2023, was $46.5 million, up from $29.0 million in the same period of 2022, indicating a 60% increase in cash outflow[112][113] - The company reported a net cash decrease of $170.9 million in cash and cash equivalents during the first half of 2023, compared to an increase of $7.4 million in the same period of 2022[28] - The accumulated deficit as of June 30, 2023, was $214.4 million, reflecting ongoing significant net losses since inception[136] Research and Development - Research and development expenses for Q2 2023 were $25,922,000, an increase of 91% compared to $13,558,000 in Q2 2022[23] - The company incurred stock-based compensation expenses of $11.2 million for the six months ended June 30, 2023, up from $4.7 million in the prior year, reflecting a 140% increase[28] - Direct research and development expenses for NVL-655 increased by $3.2 million in Q2 2023, primarily due to higher clinical and manufacturing costs[100] - The company is advancing its lead product candidates, NVL-520 and NVL-655, in clinical development, with ongoing Phase 1 trials for both[84] - NVL-520 is being evaluated in the ARROS-1 clinical trial for ROS1-positive non-small cell lung cancer (NSCLC), with preliminary data showing it was well-tolerated and demonstrated objective responses in heavily pre-treated patients[74] - NVL-655 is being evaluated in the ALKOVE-1 clinical trial for ALK-positive NSCLC, with preliminary dose-escalation data expected to be reported in Q4 2023[77] - The company has initiated IND-enabling studies for its newest product candidate, NVL-330, a HER2-selective inhibitor designed to treat tumors driven by HER2 mutations[79] Capital and Funding - The company raised $247.9 million in a follow-on public offering on November 3, 2022, selling 7,895,522 shares at a price of $33.50 per share[33] - The company expects its existing cash, cash equivalents, and marketable securities to be sufficient to fund operating expenses for at least 12 months from the date of the financial statements[35] - The existing cash, cash equivalents, and marketable securities are projected to fund operations into the second half of 2025, but additional capital will be needed for product candidates' development and commercialization[89] - The company anticipates needing to raise additional capital to complete the development and commercialization of its product candidates, as existing resources will not suffice for regulatory approval[118][119] Clinical Trials and Regulatory Risks - The company has not yet commercialized any product candidates and does not expect to generate revenue in the foreseeable future[109] - The company must demonstrate safety and efficacy through extensive clinical studies before obtaining marketing approval for its product candidates[153] - The regulatory approval process for product candidates is lengthy and unpredictable, with potential changes in approval policies that could delay marketing[167] - The company faces risks related to the discovery and development of targeted therapeutics for cancer-associated genomic alterations, which may not lead to marketable products[151] - The company may incur unplanned costs and delays in seeking marketing approval if additional clinical trials are required[150] - The company is subject to numerous foreign regulatory requirements, which can complicate the approval process and introduce additional risks[214] Competition and Market Challenges - The company faces significant competition in the oncology field, including from major pharmaceutical companies and emerging biotech firms, which may impact its ability to recruit patients for clinical trials[186] - Patient enrollment for clinical trials may be hindered by competition from other ongoing trials and the specific eligibility criteria that limit the patient population[180] - The addressable patient population for the company's product candidates may be smaller than estimated, affecting potential profitability[202] - Coverage and reimbursement from third-party payors are essential for the commercialization of products, and unfavorable practices could hinder sales[203] - The company faces significant risks related to product liability, which could adversely affect its business and financial condition if sufficient insurance coverage is not obtained[210]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-40671 NUVALENT, INC. (Exact Name of Registrant as Specified in its Charter) Delawar ...